Zegfrovy Shows Strong Results in Phase III Lung Cancer Trial

Zegfrovy (sunvozertinib), an irreversible EGFR inhibitor, has demonstrated promising outcomes in a Phase III clinical trial for first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Developed by Dizal, the global WU-KONG28 study met its primary endpoint, showing improved progression-free survival compared to standard platinum-based chemotherapy.

The randomized, open-label trial included patients from 16 countries across multiple regions, with efficacy assessed through independent central review. Detailed findings are expected to be presented at an upcoming international scientific meeting.

Zegfrovy is already approved in the United States and China for previously treated NSCLC cases with the same mutation. It has also received breakthrough therapy designation for first-line use, reflecting its potential clinical importance.

Given the complexity of EGFR exon20ins mutations, these results mark a significant step toward offering a targeted alternative to conventional chemotherapy.

29-03-2026